Articles On Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals (ASX:TLX) has announced an exclusive commercial distribution agreement with Bologna-based RADIUS for its prostate cancer investigational imaging product Illuccix.

Wall Street snaps four-day losing streak In US stock markets, the S&P 500 rose by 0.23% and the Dow Jones climbed 0.76% – snapping their four-day losing streak. The tech-heavy Nasdaq however, inched lower by 0.07%. Energy stocks were th...

13 Sep 2021 - Telix Pharmaceuticals (ASX:TLX) has found an Italian distribution partner for its prostate imaging drug, Illuccix. The biotech firm says that Radius will be its comme…

Highlights Australian benchmark index, the ASX 200, traded higher by 0.3% by mid session. Five of the 11 sectors traded in green, while the energy and material sector gained the most. Sydney Airport topped the gainers’ list on the tak...

In morning trade, the Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the rise. At the time of writing, the biopharmaceutical company’s shares are up 3% to $6.52. Why is the Telix share price rising today? Investors have been biddin...

Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx.

In the spirit of the recently-concluded Olympics and ongoing Paralympics, congratulations to the backers of the radiopharmaceuticals group for a record-breaking performance after listing this week. In raising $92 million, Clarity (ASX:CU6)...

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

Clarity Pharmaceuticals (ASX:CU6) has become one of the biggest biotech IPOs in recent memory and yesterday, it gained on debut. The company raised $92 million at $1.40 per share and it rose as much as 22% on its debut. It is the third comp...

Highlights Actinogen Medical has completed the global grant process for Xanamem with the official notification for the grant of its patent application in Brazil. Althea’s Canadian subsidiary, Peak Processing Solutions, has entered into...

Highlights Investing in renewable energy and clean energy ETFs could be a lucrative way to combat climate change. ETFs allow investors to invest in a particular sector, index, or commodity rather than a specific company. Various excha...

Ikwezi Mining (ASX:IKW) topped the latest Running Hot list with a 14-day RSI of 82, after two straight weeks where lithium stocks dominated. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength I...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Telix Pharmaceuticals Ltd (ASX: TLX) shares continue its upward trajectory, jumping 6% today. Can Telix shares keep lifting the bar?  Telix is a radiopharmaceutical company established and listed on ASX in 2017. Wait, what does it do? It is...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is soaring on the back of the company’s earnings for the first half of 2021. Right now, the Telix share price is $6.94, 6.77% higher than it was at yesterday’s close. Telix share price j...

Telix Pharmaceuticals (ASX:TLX) has announced new collaborations and studies of its investigational technologies.

While today was a better day for the ASX than the past two days, the bourse still finished slightly in the red After dropping by nearly 1% yesterday, the ASX 200 traded slightly higher for most of the day but closed 7,502 points, which was...

The ASX 200 fought back from a slow start to finish 0.12% lower in Wednesday trade, as local stocks struggle for traction after hitting new record highs this month. The major banks helped to drag the index higher, as the ASX 200 Financials...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a very strong performer on Wednesday. The molecularly targeted radiation (MTR) focused biopharmaceutical company’s shares have jumped 7% to $6.53 today. This means the Telix sha...

Highlights Incannex Healthcare has filed a registration statement for a planned IPO (initial public offering), seeking to be listed on NASDAQ under the ‘IXHL’ ticker. Telix has commenced two new studies to assess the potential utility...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Highlights Former L’Oreal MD to lead Live Verdure’s (ASX:LV1) ‘8 Seeds’ Skincare Dexus (ASX:DXS) shares FY21 results, NPAT up 17% Westpac’s (ASX:WBC) CET1 ratio in 3Q21 lowers, Bank mulls on capital return  The S&P/ASX200 is...

Highlights AVITA Medical disclosed that the US Food and Drug Administration (FDA) has authorised its request to amend the RECELL® System pivotal trial. Pharmaxis has granted Aptar Pharma an exclusive 12-month option for developing and...

Paul Hopper has been behind a number of successful oncology biotechs, and his latest venture is one of the few Australian companies in the radio-pharmaceuticals space. Hopper is best known for being behind Viraltyics which was bought by Mer...

Global markets stay cool US stocks edged higher overnight to post their fifth straight day of gains, as attention centred around geo-political concerns following the US withdrawal from Afghanistan. The Dow Jones rose by 0.31%, and the S&am...

Telix Pharmaceuticals (ASX:TLX) has announced that it has received authorisation to decommission the first of two cyclotrons housed at its licensed radiopharmaceutical production facility in Belgium and updated on a new clinical tri...

The big end of town cooled off a bit to end the week, as mining stocks eased back while the broader ASX200 drifted lower into the close. It followed two days of strong gains for the ASX200 Materials index, which gained an impressive 7.3% fo...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a subdued note. At the time of writing, the benchmark index is down 0.1% to 7,408.1 points. Four ASX shares that are not letting that hold them back a...

Most ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200 fall sharply at the open then claw back ground, before losing steam into the close of trade. Yesterday’s rotation out of large cap mining &a...

The ASX Healthcare index rose by 0.45% this morning, compared with the broader index which fell by 0.80%, helped by medicinal cannabis company AusCann (ASX:AC8). It rose by 5% in morning trading. AusCann announced it has submitted the first...

Healthcare is a constantly changing industry in which you may be asking yourself if your investments are up to date. While the healthcare sector underperformed the S&P/ASX 200 Index (ASX: XJO) in FY21, there were still some ASX-listed...

Gains for the technology sector spurred a 2.3% rise for the ASX200 in June, the eleventh month of gains for a financial year that returned 27.8%. -The ASX200 climbed 2.3% during June and the FY21 total return was 27.8%-In June Technology wa...

As we’ve covered extensively on the Fool over the past week, the S&P/ASX 200 Index (ASX: XJO) had a very successful year over the last financial year that has just passed us by. Over FY2021, the ASX 200 managed to add a very healthy 24...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Summary  The benchmark index, ASX 200,  had a decent run in June, with a ~2.4% growth.     Several ASX-listed players had a strong June 2021 driven by key developments and are poised to progress further.  Sayona Mining, Liontown,...

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

In late morning trade, the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a positive note. At the time of writing, the benchmark index is up 0.25% to 7,294.5 points. Four ASX shares climbing more than most today are li...

Telix Pharmaceuticals (ASX:TLX) says a first patient has been dosed in a phase one study of TLX250-CDx ( 89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been among the worst performers on the All Ordinaries on Monday. The biopharmaceutical company’s shares were down as much as 14% to $5.53 at one stage. Despite this, the Telix share...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and trading lower. At the time of writing, the benchmark index is down 0.3% to 7,363.5 points. Four ASX shares that are not letting that hold them back are liste...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is edging lower on Thursday morning despite the release of a positive announcement. At the time of writing, the biopharmaceuticals company’s shares are down slightly to $5.61. What did T...

Summary Neuroprotective drug developer Argenica Therapeutics commenced trading on the ASX after a well-supported AU$7 million capital raising. The Company disclosed that the ASX listing would allow it to develop its novel neuroprotecti...

One area of the share market that is home to a number of quality options for investors is the mid cap space. But which ones should you consider buying? Two to get better acquainted with are listed below: Hipages Group Holdings Ltd (ASX: H...

Tech stocks push Wall Street near all-time highs All major US indices rose on Friday to close near their all-time highs, with tech stocks being the main driver. The Dow Jones rose by 0.52%, just 0.1% shy of its all-time high. S&P 500 cl...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is having a negative day despite announcing an exciting co-promotion agreement. At the time of writing, the biotechnology company’s shares are fetching for $4.35, down 2.25%. Telix expand...

The diagnostics imaging industry has come a long way since the days of X-rays and CT scans – two technologies that have been around for decades. Although they have not been replaced entirely, a breed of new ASX small caps have emerged over...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is rocketing higher, nearing on its all-time high of $4.80. This follows the biotechnology company’s update on its bone marrow conditioning investigational candidate, TLX66. At the time...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. At the time of writing, the benchmark index is up 0.5% to 7,082.4 points. Four ASX shares that are climbing more than most...